Home Blog Page 444

XTransfer Joins in Chile Fintech Forum 2026

By
Advertorial Desk
-

Brings X-Net to Latin America to Support SME Foreign Trade Payments


SANTIAGO, CHILE – Media OutReach Newswire – 12 May 2026 – XTransfer, the world’s leading B2B cross-border trade payment platform, participated in the Chile Fintech Forum 2026 as Platinum sponsor and introduced X-Net in Latin America for the first time. X-Net is a globally unified B2B cross-border settlement network and risk management platform designed to connect banks and financial institutions with SMEs, supporting more efficient, secure, and inclusive cross-border payment solutions as China–Latin America trade continues to expand.

Violas Xiao, Singapore and LatAm CEO of XTransfer, speaks at Chile Fintech Forum.
Violas Xiao, Singapore and LatAm CEO of XTransfer, speaks at Chile Fintech Forum.

Despite rising trade volumes, SMEs still faced “last-mile” friction in cross-border payments. Fragmented domestic rails and local banking practices often required payments to pass through multiple intermediaries and currencies, increasing cost, processing time, and operational failure points. Reliance on USD settlement further added double-conversion fees and FX constraints that could trap working capital and reduce margin predictability. Meanwhile, tighter fraud controls and stricter Anti-Money Laundering (AML) requirements made compliance checks more complex and harder to scale, which could leave legitimate businesses facing friction with onboarding difficulties, account restrictions, or frozen funds.

Introducing X-Net
XTransfer developed X-Net as an infrastructure purpose-built for B2B cross-border trade. The hybrid network works with regulators, banks, and payment institutions to advance standards for fund-flow design, product integration, and risk control. As a settlement and risk-control layer linking financial institutions to import-export enterprises, X-Net aims to standardise collections, payouts, and compliance workflows across participants, helping SMEs access secure, compliant, and seamless payment infrastructure once reserved for multinationals.

The LatAm market potential
Latin America is growing and upgrading fast. XTransfer data shows collections from the region rose 94% year-on-year in 2025, outpacing China’s 8% export growth there and signalling a shift toward secure, compliant collections. The XTransfer Export PMI, a sample survey of XTransfer’s 800,000 SME users, selecting over 3,000 companies nationwide, also points to strong fundamentals, with Latin America’s export order index at 56.47 and price index at 57.81 in March 2026, above global readings of 53.85 and 56.15.

Violas Xiao, Singapore and LatAm CEO of XTransfer, said, “Emerging markets are central to XTransfer’s expansion, and in Latin America. Next, we’ll deepen coverage in Brazil and Mexico while expanding into growth markets like Chile, Colombia, Peru, and Argentina, improving minor-currency liquidity and risk automation so SMEs can pay and collect more predictably and compliantly.”
Hashtag: #XTransfer #Chile #FintechForum #Crossborder #Payment #SMEs





The issuer is solely responsible for the content of this announcement.

About XTransfer

XTransfer, the world’s largest B2B cross-border trade payment platform with over US$60 billion TPV in 2025, according to CIC. In Latin America, XTransfer operates in partnership with local banks and financial institutions across Brazil, Chile, Colombia, Mexico, and Peru, to give SME buyers access to local payment networks, enabling them to pay their global suppliers using bank transfers, digital wallets, and instant payment methods such as Brazil’s Pix.

Jamf unveils 2026 Security 360 Report: An analysis of the latest Mac and mobile security threats

By
Advertorial Desk
-

The annual report identifies vulnerable applications and critically out-of-date operating systems as top concerns for organizations.


HONG KONG SAR – Media OutReach Newswire – 12 May 2026 – Jamf, the standard in managing and securing Apple at work, today released its annual Security 360 Report, separated into analyses for mobile and macOS environments. The report, derived from the analysis of real-world incidents, threat research, and industry events from the past year, spotlights the diverse and impactful attack vectors that attackers use to cause harm with insight for security leaders and IT practitioners to protect both Mac and mobile fleets.

“Our goal with this research is to spread awareness among security leaders regarding the risks impacting their organizations so that they can ensure threat detection, compliance enforcement and response capabilities are aligned with their Mac and mobile devices,” said Michael Covington, Vice President of Portfolio Strategy at Jamf. “Jamf remains deeply committed to not only protecting our customers, but also providing the broader security community with valuable insights for greater safety and success with Mac and mobile devices.”

Jamf’s mobile device threat analysis is structured into four categories.

Device vulnerabilities

Over 12 months, Jamf found that 53% of organizations had devices with critically out-of-date operating systems.

Application risks

95% of applications assessed contained at least one medium-severity vulnerability. Furthermore, 62% of assessed applications requested dangerous permissions, with 21% containing privacy-impacting behaviors.

Network and web risks

Phishing continues to flourish as a top attack vector for adversaries, as 25% of organizations had a user fall victim to a phishing link and 18% had users connect to risky hotspots.

Advanced persistent threats (APTs)

Advanced threat groups are stacking vulnerabilities to create sophisticated exploits. Through zero-click attacks, browser attacks, Apple and Android devices remain an active threat vector.

Threat trends facing macOS environments

Mac malware and threats

44% of Mac devices are experiencing malicious network traffic and 26% of organizations were impacted by cryptojacking attacks. Jamf Threat Labs added over 26,000 malware samples to their database in 2025.

In 2025, trojans represented about half of all attacks, while trojans, infostealers, adware, and potentially unwanted applications account for 90% of all attacks on Mac devices.

Most common Mac malware families

In 2025, PuAgent was the most common family of malware at 16.41%.

Hashtag: #software #apple

The issuer is solely responsible for the content of this announcement.

Laos, Region Intensify Crackdown on Online Scam Networks

By
Phoudasack Vongsay
-
A picture to illustrate the ASEAN.

Lao authorities have intensified operations against alleged telecom and online scam networks in recent weeks, with hundreds of suspects detained in major crackdowns across several provinces.

According to authorities in Bokeo province, police arrested 230 individuals linked to alleged call center scam operations during raids carried out between 4 and 11 May in Houayxay and Tonpheung districts. The suspects included nationals from Laos, China, Myanmar, the Philippines, Malaysia, and Indonesia.

The largest operation took place on 11 May in Tonpheung district, where authorities detained 159 suspects, including 106 Lao nationals. Earlier raids conducted on 4 and 5 May in Houayxay district led to the arrest of another 71 suspects, most of them Chinese and Myanmar nationals.

Separately, authorities on 7 May transferred 605 suspects linked to alleged computer fraud operations in Savannakhet province to Vientiane for further investigation. Officials said the group included individuals from eight nationalities, including Chinese, Thai, Vietnamese, Cambodian, Myanmar, Malaysian, Taiwanese, and South Korean nationals.

Authorities have not yet released full details regarding charges or the scope of the alleged fraud operations as investigations continue.

The operations form part of a broader nationwide campaign targeting cybercrime and online fraud networks.

On 30 April, Minister of Public Security Vanthong Kongmany visited the Golden Triangle Special Economic Zone, Bokeo, to strengthen enforcement efforts and prevent scam operations from re-establishing in the area. During the visit, authorities called for tighter organisation, improved monitoring, and continued training for enforcement officers.

The intensified crackdown follows Prime Minister Sonexay Siphandone’s directive issued in late April ordering authorities nationwide to strengthen action against online scams and cybercrime activities.

Regional Crackdowns Across Southeast Asia

The operations in Laos come amid wider regional enforcement efforts targeting online scam compounds and cyber fraud networks across Southeast Asia.

In Cambodia, immigration authorities detained 994 foreign nationals from 16 countries, including Lao citizens, during a large-scale operation on 10 May targeting alleged online scam activities, illegal residency, and individuals with outstanding sentences.

Meanwhile, Indonesian authorities arrested around 210 foreign nationals, including 47 women, in Batam on 6 May during an immigration surveillance operation linked to suspected online investment fraud activities. The suspects reportedly included nationals from Vietnam, China, and Myanmar.

The recent operations signal growing regional coordination to dismantle online scam networks operating across borders in Southeast Asia.

Bora Group to Acquire MacroGenics’ GMP Manufacturing Operations for $122.5M

By
Advertorial Desk
-

Securing Maryland-Based Drug-Substance Facility and Existing Commercial Orders to Scale the Group’s Integrated Technology Platform


HONG KONG SAR – Media OutReach Newswire – 12 May 2026 – Bora Pharmaceuticals (“Bora” or “Bora Group”; TWSE: 6472; OTCQX: BORAY) today announced that its Board of Directors has approved the acquisition of the GMP manufacturing operations, including the CDMO business, of MacroGenics, Inc. (NASDAQ: MGNX), for total consideration of US$122.5 million, subject to customary working capital adjustments, and a contingent consideration of up to $5 million based on future customer orders. The transaction includes a biologics drug substance manufacturing facility located in Rockville, Maryland and an associated warehousing center in Frederick, Maryland. Upon closing of the acquisition, the Company will sign a long-term CDMO Service Agreement with MacroGenics.

Following closing, Bora Group intends to leverage the Rockville Site in cooperation with Tanvex Biopharma (TWSE: 6541), which operates the Group’s biologics CDMO franchise under the “Bora Biologics” brand. Together with Bora’s sterile drug product capabilities, this is expected to scale the Group’s end-to-end biologics platform.

The Rockville facility has operated as an outsource manufacturing partner since 2022 and is equipped with five 2,000-liter and two 500-liter single-use bioreactors and fully integrated QC and analytical laboratories and has been inspected by both the U.S. FDA and Japan’s PMDA. From the transaction, Bora is expected to assume a substantial backlog for the size of its Bora Biologics CDMO business, including commercial-stage monoclonal antibody programs, clinical-stage programs, and a strong project pipeline. Commercial manufacturing currently accounts for more than half of the site’s revenue.

“This acquisition marks a pivotal step in strengthening Bora’s integrated biologics CDMO platform in the United States”, said Bobby Sheng, Chairman and CEO of Bora Group. “With the addition of the Rockville site, Bora Biologics total drug substance capacity would be 20,000-liter (SUB) and Bora Group will integrate our in-house DS (Drug Substance) and DP (Drug Product) capabilities and network investments over the next 12 to 18 months to offer global biotech customers a seamless offering allowing customers to advance programs from development through commercial supply with one single partner.”

Bora’s Board of Directors has authorized the Chairman to finalize the transaction in line with market conditions and the regulatory environment. For the year ended December 31, 2025, MacroGenics reported contract manufacturing revenue of $52.6 million.
Hashtag: #BoraPharmaceuticals

The issuer is solely responsible for the content of this announcement.

About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

Exterro Launches Industry’s First Autonomous AI Engine to Eliminate Up to 95% of manual Subpoena Work and Reclaim 7,500 Enterprise Hours

By
Advertorial Desk
-

Exterro Subpoena Manager unlocks $500,000+ in potential annual savings; puts legal and IT teams on a definitive path toward a fully autonomous enterprise architecture.

PORTLAND, Ore., May 12, 2026 /PRNewswire/ — Legal’s manual relay race is over. Exterro, the leader in unified data risk management software, today launched Exterro Subpoena Manager, an agentic AI solution that transforms the slow, disconnected process enterprises face when managing subpoenas, into a faster, smarter, and more controlled system of execution. This solution, which moves beyond the “AI as assistant” paradigm by embracing truly autonomous agentic workflows with built-in human oversight, reduces subpoena intake and routing tasks from 90 minutes down to as little as five minutes.

Exterro Subpoena Manager is the first step in removing manual workloads for organizations interested in leveraging a more autonomous platform for risk management. It ties to Exterro’s visionary new framework, ARMOUR (Autonomous Risk Management, Orchestration, and Unified Response) which the company outlined earlier today. With the immediate availability of Exterro Subpoena Manager, Exterro signals that ARMOUR is not a roadmap or a theoretical vision. It marks the end of manual legal coordination, replacing routine workflow steps with AI-driven execution that completes complex workflows today, transparently and defensibly.

 “The legal technology market is currently saturated with AI tools that offer assistance but stop short of true execution. Exterro’s approach is fundamentally different; they have a unique vision that moves beyond the noise to solve a pervasive operational bottleneck,” said Ryan O’Leary, Research Director, Privacy and Legal Technology at IDC. “By applying autonomous AI to workflows like subpoena response, Exterro is delivering immediate, game-changing value that allows legal teams to pivot from manual coordination to strategic orchestration.”   

The Economics of Action: Over $500,000 in Immediate Impact

While the industry has been flooded with AI chatbots that offer answers without accountability, Exterro Subpoena Manager delivers tangible business outcomes in the present tense. For large organizations in highly regulated fields, this is a shift away from manual drudgery to autonomous execution is designed to deliver significant improvements to the bottom line:

  • Up to 95% Reduction in Manual Work: Exterro Subpoena Manager removes the manual intake labor that slows teams down, reducing time spent on the process by up to 95%.
  • Up to 7,500 Hours of Manual Labor Reduced: Handling 100 subpoenas weekly costs large organizations 7,500 hours annually, which is the equivalent of nearly four full-time employees lost to administrative tasks. Exterro Subpoena Manager slashes this burden to just 417 total hours of strategic oversight per year.
  • Over $500,000 in Potential Savings: At a processing rate of $75/hour, the cost to organizations handling large volumes of subpoenas can exceed $500,000 annually. Exterro Subpoena Manager collapses that spend, reducing these costs for high-volume enterprises every year.
  • Up to 10x Operational Throughput: By automating the mechanical clerical effort associated with inputting subpoenas, routing information requests to the right departments, following up with them automatically, then finally preserving, collecting, and reviewing relevant data before production, legal teams can handle ten times the volume of subpoena-related work.

Exterro Subpoena Manager utilizes governed autonomous agents to ingest subpoenas from any channel, instantly extracting critical deadlines and matter details to create structured records without manual data entry. It then orchestrates the entire downstream execution by correlating data across enterprise systems to drive preservation, collection, and review while keeping legal teams in strategic command of every final approval.

Stop Knowing. Start Doing.

“This is the first time legal work can be actually executed across complex enterprise systems via conversation,” said Ajith Samuel, Chief Product Officer at Exterro. “We aren’t asking legal teams to ‘consider’ options or merely chat with a bot; we are giving them an engine designed to achieve business outcomes under their oversight. Exterro Subpoena Manager is the first proof of what the ARMOUR framework can do in practice: it eliminates disconnected steps and accelerates execution today.”

A Blueprint for the Autonomous Enterprise

Transforming how legal teams manage subpoenas is the innovative, foundational first step in realizing Exterro’s AI visionary framework, ARMOUR, and serves as the engine for how litigation, internal investigations, and data governance will be tackled moving forward. With Exterro Subpoena Manager, the agents, securely connected to the enterprise’s data sources, do far more than offer suggestions. They act on them, completing each step in the subpoena response process and stopping for human oversight as designed. As the system progressively learns how organizations want to manage the workflow, the agents can, if desired, autonomously execute more and more additional steps in the workflow before checking in with the user.

Going forward, customers will soon be able to manage additional complex, multi-step data risk workflows across the Exterro platform with natural language conversations, rather than clicking through menu-driven interactions in disparate software solutions.

If you’re interested in helping shape the future of AI in legal, you can apply to participate in our exclusive preview program here.

Why Exterro? The Architecture of Reality

Exterro is uniquely positioned to deliver autonomous AI through 13 years of data management expertise and AI innovation, with a proven history of connecting many moving parts of an organization’s data infrastructure. Unlike generic tools bolted on in a silo, Exterro’s platform natively bridges the gap between disconnected systems to ensure data is connected across commonly collected data sources for comprehensive, accurate decision-making.

  • Unified Execution: Exterro is a platform purpose-built to unify legal hold, collection, processing, and response in one place, replacing workflow sprawl with a centralized system of record.
  • Deep Enterprise Connectivity: With over 190 connectors, Exterro acts on data where it already resides, behind your firewall, ensuring outcomes are reliable, secure, and defensible.
  • Human-Led Orchestration: This isn’t a “black box,” it’s a digital workforce that reports to you. While the system handles the manual heavy lifting, legal professionals act as the final decision-makers. You remain in the driver’s seat, providing the final strategic sign-off on every action while the system learns and optimizes from your expert judgment.

Experience the End of Manual Subpoena Response at CLOC 2026

Exterro will officially debut Exterro Subpoena Manager and autonomous AI at the Corporate Legal Operations Consortium (CLOC) Global Institute in Chicago. Witness the next-generation of legal operations, happening now.

Learn more about Exterro Subpoena Manager at exterro.com/e-discovery-software/subpoena-manager.

Exterro Subpoena Manager is a SaaS solution offering flexible on-demand or bulk pricing based on the volume of subpoenas processed.

About Exterro 

Exterro empowers organizations to manage data risks with a complete platform for e-discovery, data privacy, cybersecurity and governance, and digital forensics. Unlike any other software provider, Exterro makes it easy for organizations to understand their data and take swift action.  Exterro’s AI-driven solutions provide accurate, actionable insights, enabling businesses to support compliance efforts, reduce risks, and streamline operations while lowering costs. With Exterro, organizations gain the clarity and confidence needed to address their most critical data challenges. For more information, visit www.exterro.com.

Media Contacts:

Hazel Ramirez
Plat4orm
hazel@plat4orm.com

Anamika Dhirendrakumar   
anamika.dhirendrakumar@exterro.com

As CFD Brokers Expand Card-Based Payment Use Cases, Vantage Moves Early with Virtual Card Service

By
Advertorial Desk
-

PORT VILA, Vanuatu, May 12, 2026 /PRNewswire/ — As CFD platforms evolve beyond market access, account-linked services and card-based payment use cases are increasingly integrated into fintech. Vantage Markets has launched the Vantage Virtual Card, an account-linked card enabling eligible clients in selected jurisdictions to use available account balances for everyday payments at supported merchants, subject to laws, regulations, issuer approval, card network rules, and programme terms.

As a multi-asset CFD broker, Vantage focuses on technology-driven infrastructure, efficient execution, access to liquidity, and global connectivity. The Virtual Card lets eligible clients access card-based payment functionality across supported payment scenarios.

Once activated, clients may use the Virtual Card at merchants accepting the relevant card network, including online shopping, travel, entertainment, digital content, and food delivery. Where available, it can be added to Google Pay, connecting account access with daily spending.

As CFD Brokers Expand Card-Based Payment Use Cases, Vantage Moves Early with Virtual Card Service
As CFD Brokers Expand Card-Based Payment Use Cases, Vantage Moves Early with Virtual Card Service

The card is provided by third-party service providers for technology, integration, and payment infrastructure. Vantage acts in a facilitation and marketing capacity, extending account functionality into broader payment use cases, subject to applicable laws and partner approval.

The launch aligns with a fintech trend linking platform capabilities, card-based payments, and regulated third-party infrastructure. Vantage supports ongoing development of account functionality and platform features.

A limited-time promotional campaign in selected markets offers activation rewards and cashback incentives, subject to programme terms, eligibility, and regulations.

The Vantage Virtual Card connects trading-related account functionality with real-world payments. Vantage will continue enhancing platform capabilities through technology integration, third-party infrastructure, and product innovation.

About Vantage Markets

Vantage Markets is a multi-asset broker offering CFDs across forex, commodities, indices, shares, and digital assets. It delivers fast execution, liquidity access, and platform solutions for traders of all experience levels.

Risk Warning: CFDs are complex and carry a high risk of losing money rapidly due to leverage. Ensure you understand the risks before trading.

Disclaimer: This content is informational and not financial advice. The Vantage Virtual Card is provided by third-party issuers and may not be available in all jurisdictions. Access is subject to laws, eligibility, and issuer approval. Vantage does not provide payment services or issue the card. This content is not for residents of jurisdictions where CFD trading or related services are restricted.

CapBridge Pte Ltd Collaborates with Sun Life Singapore for HNWIs

By
Advertorial Desk
-

SINGAPORE – Media OutReach Newswire – 12 May 2026 – CapBridge Pte Ltd (“CapBridge”), a one-stop digital investment platform and a member of FOMO Group, has collaborated with Sun Life Assurance Company of Canada Singapore Branch (“Sun Life Singapore”) to distribute Sun Life Singapore’s SunBrilliance insurance solutions to global High Net Worth individuals (HNWIs) and family offices.
Backed by 160-year heritage and superior AA financial rating from S&P, Sun Life brings institutional-grade financial strength and security to this collaboration.

Advanced IUL Solutions for HNWIs Legacy Planning
This collaboration addresses the increasing demand for sophisticated, cross-border legacy planning solutions among High-Net-Worth individuals across Asia. At the core of the collaboration is Sun Life Singapore’s SunBrilliance Indexed Universal Life II (IUL), a permanent life insurance designed to meet the complex needs of modern wealth preservation:

Dual-Account Flexibility: Premiums can be allocated between a fixed-interest account and an indexed account, giving HNW families greater flexibility in capital utilisation and liquidity management.

Downside-Protected Growth: The indexed account offers upside potential linked to the performance of S&P 500 index, with a guaranteed floor (typically 0%), ensuring a stable safety net regardless of market conditions.

Strategic Legacy Planning: Together, capital liquidity and downside protection provide the long-term certainty essential for multi-generational wealth transfer.

Digitally Enabled for a Global Client Base
Through a streamlined onboarding framework, the collaboration enhances efficiency and the overall client experience, enabling clients across Southeast Asia and other key markets to manage international insurance solutions more seamlessly. This approach improves accessibility while maintaining a robust and compliant framework, further reinforcing CapBridge’s role as a gateway to cross-border legacy planning.[YA1]
“High-Net-Worth families today are looking for more than just a policy, they want long-term certainty and structures that can adapt as their lives evolve,” said Janet Liu, CEO of CapBridge. “This collaboration with Sun Life Singapore is a direct response to that demand for well-structured, scalable solutions. By integrating Sun Life Singapore’s IUL offering with our remote-enabled capabilities, we’re providing the essential balance of capital liquidity and market protection that global families require to secure their wealth for the next generation.”

Strengthening FOMO Group’s Integrated Financial Ecosystem
This addition aligns with FOMO Group’s broader vision of building a more integrated digital finance ecosystem. By deepening its insurer partnerships, CapBridge further strengthens the Group’s ability to deliver end-to-end financial solutions across payments, investments, and capital markets. This approach addresses the evolving requirements of HNWIs by providing unified access to comprehensive multi-asset investments including institutional bonds, structured notes, physical gold, and digital assets within a well-regulated framework.

Hashtag: #CapBridge #FOMOGroup



The issuer is solely responsible for the content of this announcement.

About CapBridge

CapBridge, a member of FOMO Group, is a leading digital investment platform headquartered in Singapore. As a Capital Markets Services licensee, CapBridge is regulated by the Monetary Authority of Singapore (MAS) to offer top-tier funds, digital asset funds, stocks, bonds, equities, and arrange life insurance products. It provides mass affluent, HNWIs, and institutional clients with seamless access to both private and public markets, meeting clients’ diverse asset allocation needs.For more information, please visit. For media inquiries, please contact .

About Sun Life

Sun Life is a leading international financial services organisation providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of December 31, 2025, Sun Life had total assets under management of CAD1.60 trillion. For more information, please visit www.sunlife.com. For more information about Sun Life Singapore, please visit .
Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Sun Life Important Information:
Buying a life insurance policy is a long-term commitment. An early termination of the policy usually involves high costs and the surrender value payable (if any) may be less than the total premiums paid. This media release is for general information only and does not take into account the specific investment objectives, financial situation or particular needs of any specific person. You should seek advice from a financial adviser regarding the suitability of the policy before making a commitment to purchase. In the event that you choose not to do so, you should consider whether the product in question is suitable for you. This media release is not a contract of insurance. Please refer to the policy contract for the exact terms and conditions, specific details and exclusions.
The policy mentioned in this media release are protected under the Policy Owners’ Protection Scheme which is administered by the Singapore Deposit Insurance Corporation (SDIC). Coverage for your policy is automatic and no further action is required from you. For more information on the types of benefits that are covered under the scheme as well as the limits of coverage, where applicable, please contact us or visit the Life Insurance Association, Singapore or SDIC websites (www.lia.org.sg) or (www.sdic.org.sg).
This advertisement has not been reviewed by the Monetary Authority of Singapore. Information is correct as at April 2026.
While Sun Life believes that the information set out here is correct and accurate as at the date on which it is issued, Sun Life does not guarantee the correctness, accuracy or completeness of its contents. Further, Sun Life does not assume any responsibility, and has no obligation, to update this media release or inform recipients of its updated contents in due course, if any of its contents changes. Sun Life is not liable for any loss, damages or expenses that may be incurred from reliance upon the contents herein.
No part of this media release shall be construed as advice from Sun Life or an indication of whether any product referred to herein is suitable for any particular individual or entity. This media release does not constitute solicitation or an offer to purchase any product mentioned herein. The suitability of a product for any person needs to be considered bearing in mind the relevant person’s own circumstances and needs, and as such, qualified professional advisors, such as lawyers, accountants, tax and financial advisors, should be engaged by the relevant person as (s)he deems fit before (s)he decides whether or not to purchase any product. Except as expressly set out, Sun Life does not make any representations as to the selling or other restrictions that apply to life insurance products that it offers. Distributors have the sole responsibility to acquaint themselves at all times with, and comply fully with, relevant laws, regulations and other requirements, as applicable, in relation to distributing insurance products.
Sun Life Assurance Company of Canada is an insurance company federally incorporated in Canada, with OSFI Institution Code F380 and its registered office at 1 York Street, Toronto, Ontario, Canada M5J 0B6. It is regulated by Office of the Superintendent of Financial Institutions, Canada. Sun Life Assurance Company of Canada Singapore Branch (UEN T19FC0132B) is registered with the Accounting and Corporate Regulatory Authority of Singapore as a foreign company, with its registered office at 50 Raffles Place, #26-04 Singapore Land Tower, Singapore 048623. It is licensed and regulated by the Monetary Authority of Singapore. Where Sun Life Assurance Company of Canada Singapore Branch is referred to as “Sun Life Singapore”, this is strictly for marketing and branding purposes only, and no legal significance is expressed or implied. Sun Life Assurance Company of Canada is a member of the Sun Life group of companies. The Sun Life group of companies operates under the “Sun Life” name. Sun Life Financial Inc., the publicly traded holding company for the Sun Life group of companies, is not a product offering company and is not the guarantor of the obligations of its subsidiaries.
© 2026 Sun Life Assurance Company of Canada. All rights reserved. The name Sun Life and the globe symbol are registered trademarks of Sun Life Assurance Company of Canada.

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

By
Advertorial Desk
-

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide

Agreements include 13 programs with the potential to address significant unmet patient needs and support long‑term growth

SHANGHAI and PRINCETON, N.J., May 12, 2026 /PRNewswire/ — Hengrui Pharma (“Hengrui”) (600276.SH; 01276.HK) and Bristol Myers Squibb (“BMS”) today announced the companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology, with the goal of accelerating discovery and development of innovative medicines for the benefit of patients worldwide.

The agreements include four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five innovative assets to be jointly discovered and developed by both companies, leveraging Hengrui’s discovery engine and platform technologies across several innovative modalities. Hengrui has the option to co-develop select assets and the potential to conduct certain commercialization activities globally with BMS.

Under the collaboration, BMS obtains exclusive worldwide rights to the Hengrui‑originated assets outside Chinese mainland, Hong Kong SAR, and Macau SAR (the “Hengrui Territory”), while Hengrui obtains exclusive rights to the BMS‑originated assets within the Hengrui Territory, with BMS retaining rights for the rest of the world. Hengrui will be fully responsible for early clinical development to accelerate clinical proof of concept for these programs.

Aligned with the collaborative innovation strategies of both BMS and Hengrui, these agreements reflect the companies’ continued focus on advancing innovative science through partnership in areas of significant unmet medical need. The collaboration brings together BMS’s differentiated research and discovery strengths, global clinical development capabilities, regulatory expertise, and commercial scale with Hengrui Pharma’s discovery engine, platform technologies, and efficient early-stage development expertise, enabling the advancement of a broad portfolio of high-value programs.

“This broad strategic collaboration reflects a highly synergistic collaboration between two global innovators with complementary strengths. By leveraging Hengrui’s growing R&D capabilities and proven efficiency in discovering and advancing innovative therapies, we are poised to advance the best of both pipelines,” said Frank Jiang, MD, PhD, Executive Vice President and Chief Strategy Officer of Hengrui Pharma. “It also reflects Hengrui’s continued commitment to strengthen our global presence. Together, we aim to deliver meaningful benefits to patients worldwide.”

“This strategic collaboration reflects our commitment to advancing innovative science while maintaining a disciplined approach to portfolio management,” said Robert Plenge, MD, PhD, Executive Vice President and Chief Research Officer, Bristol Myers Squibb. “By leveraging complementary capabilities across geographies, we aim to accelerate early clinical learning and make informed decisions that support driving top tier growth in the next decade and, ultimately, our mission to deliver medicines that help patients prevail over serious diseases.”

Under the terms of the agreement, BMS will pay Hengrui up to $950 million, including a $600 million upfront payment, a $175 million first anniversary payment, and a second contingent anniversary payment of $175 million in 2028. The potential total value of the agreement is up to approximately $15.2 billion, including the exercise of available options for the joint discovery programs and the achievement of applicable development, regulatory, and commercial milestones for all programs. In addition, Hengrui is eligible to receive tiered royalties on net sales of products commercialized outside the Hengrui Territory.

The transaction is subject to review under the Hart‑Scott‑Rodino Antitrust Improvements Act and other customary closing conditions. The parties expect that the agreement will close in the third quarter of 2026.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the strategic collaboration and license agreements with Hengrui Pharma.  All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our actual future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of, and opportunities related to, the agreement may not be realized by Bristol Myers Squibb or may take longer to realize than anticipated, that Bristol Myers Squibb may fail to discover and develop any commercially successful product candidates through the agreement, and that assets or product candidates may not achieve their primary study endpoints or receive regulatory approval for the indications described in this release in the currently anticipated timeline or at all and, if approved, whether such product candidate treatment or combination treatment for such indications described in this release will be commercially successful.

No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

About Hengrui Pharma: Innovation to Benefit Patients Worldwide
Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

Hengrui Pharma Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that reflect Hengrui Pharma’s beliefs or expectations about the future or future events as of the respective dates indicated therein (“forward-looking statements”). These forward-looking statements are based on a number of assumptions about Hengrui Pharma’s operations, its future development plans, market (financial and otherwise) conditions and growth prospects, and are subject to significant risks, uncertainties and other factors beyond Hengrui Pharma’s control, and accordingly, actual results may differ materially from those contemplated by these forward-looking statements. No reliance should be placed on such statements, which reflect the view of the management of Hengrui Pharma as at the date of this press release. Hengrui Pharma does not undertake any obligation to update these forward-looking statements for events/or circumstances that occur subsequent to such dates.

1...443444445...6,562Page 444 of 6,562